Remove 2021 Remove Prospecting Remove Side effects
article thumbnail

Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom

Pharmaceutical Technology

A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has unanimously voted in support of Eisai and Biogen’s Leqembi and its clinical benefit in patients with early Alzheimer’s disease , raising the drug’s full approval prospects. Leqembi is the second drug developed by Biogen and Eisai for the treatment of Alzheimer’s disease.

article thumbnail

Overcoming Sales Objections Part 1: Pharma Sales Challenges

Pharmaceutical Representative Training

Introduction Every sales professional has experienced deals collapsing at the last minute due to objections from prospects. In the competitive world of pharmaceutical sales, effectively handling customer objections is crucial for success. There are times when your prospect will have multiple objections at once.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

This randomised, open label-controlled multicentre clinical trial was conducted across 21 sites in Spain from 2021 to 2023. The specific representation of these events differed between the treatments, highlighting potential differences in side effect profiles that should be explored in further studies. 2021; 27 (2): S1-S21.

Safety 111
article thumbnail

Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape

Pharmaceutical Technology

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. In September 2021, the same study reported a 100% seroconversion rate after a booster was given to the participants.

article thumbnail

GSK shelves arthritis blockbuster hope otilimab after lacklustre data

pharmaphorum

It’s a disappointing outcome for a programme that GSK said in 2021 could potentially generate £1 to £2 billion in peak sales because of the serious unmet need in RA patients. GSK licensed otilimab from German biotech MorphoSys in 2013 in a deal valued at up to €423 million, including around €23 million upfront. Daprodustat backed.

article thumbnail

Adherence to Treatment: Making the Most of the First 30 Days

PM360

Indeed, in research from the 2021 PURE Report, 3 50% of the patients responding found the therapy discussion to be a highly stressful period in their treatment journey. Hospital Admissions Associated with Medication Non-Adherence: A Systematic Review of Prospective Observational Studies.” Start Patient Support Immediately.

article thumbnail

Precision Medicine Needs an Overhaul

PM360

Between 2015 and 2021, over a quarter of the drugs approved by the US Food and Drug Administration (FDA) were associated with specific biomarkers. As of 2021, 537 million adults were living with diabetes worldwide. During the period from 2008 through 2020, the number of precision medicines in the US increased from 5 to 285.